NEW YORK (GenomeWeb) – A team of researchers from Pfizer, the University of Glasgow, and Oxford BioDynamics have developed a new method to discern who will respond poorly to methotrexate, a drug sold by Pfizer that is commonly used to treat people with onset rheumatoid arthritis.

The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.